Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.

Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, Borgman CA, Stelow EB, Lowrey BT, Chopivsky ME, Gilmer TM, Parsons JT, Bauer TW.

Neoplasia. 2013 Feb;15(2):143-55.

PMID:
23441129
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer.

Lindberg JM, Newhook TE, Adair SJ, Walters DM, Kim AJ, Stelow EB, Parsons JT, Bauer TW.

Neoplasia. 2014 Jul;16(7):562-71. doi: 10.1016/j.neo.2014.06.004.

PMID:
25117978
[PubMed - in process]
Free Article
3.

Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI.

Clin Cancer Res. 2010 Feb 1;16(3):912-23. doi: 10.1158/1078-0432.CCR-09-1324. Epub 2010 Jan 26.

PMID:
20103665
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD.

Cancer Res. 2011 May 15;71(10):3635-48. doi: 10.1158/0008-5472.CAN-10-2430. Epub 2011 Apr 4.

PMID:
21464044
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.

Neoplasia. 2012 Feb;14(2):121-30.

PMID:
22431920
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.

Song JY, Kim CS, Lee JH, Jang SJ, Lee SW, Hwang JJ, Lim C, Lee G, Seo J, Cho SY, Choi J.

Invest New Drugs. 2013 Dec;31(6):1458-65. doi: 10.1007/s10637-013-0030-0. Epub 2013 Sep 26.

PMID:
24068620
[PubMed - indexed for MEDLINE]
7.

Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.

Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM.

Radiother Oncol. 2009 Dec;93(3):639-44. doi: 10.1016/j.radonc.2009.09.006. Epub 2009 Oct 23.

PMID:
19853943
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.

Guo XF, Zhu XF, Zhong GS, Deng BG.

Dis Esophagus. 2013 Jul;26(5):487-95. doi: 10.1111/j.1442-2050.2012.01332.x. Epub 2012 Mar 27.

PMID:
22458639
[PubMed - indexed for MEDLINE]
9.

Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.

Singla S, Pippin JA, Drebin JA.

Oncol Rep. 2012 Dec;28(6):2211-6. doi: 10.3892/or.2012.2053. Epub 2012 Sep 24.

PMID:
23007710
[PubMed - indexed for MEDLINE]
10.

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.

Cancer Res. 2001 Dec 15;61(24):8887-95.

PMID:
11751413
[PubMed - indexed for MEDLINE]
Free Article
11.

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.

Cancer Res. 2006 Apr 1;66(7):3802-12. Erratum in: Cancer Res. 2010 Jan 15;70(2):852-3.

PMID:
16585207
[PubMed - indexed for MEDLINE]
Free Article
12.

Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.

Sambade MJ, Kimple RJ, Camp JT, Peters E, Livasy CA, Sartor CI, Shields JM.

Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):575-81. doi: 10.1016/j.ijrobp.2009.12.063.

PMID:
20457354
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC.

Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11.

PMID:
18334972
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

EGFR and HER2 inhibition in pancreatic cancer.

Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N.

Invest New Drugs. 2013 Jun;31(3):558-66. doi: 10.1007/s10637-012-9891-x. Epub 2012 Oct 18.

PMID:
23076814
[PubMed - indexed for MEDLINE]
15.

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, Cusack JC Jr.

Clin Cancer Res. 2008 Aug 15;14(16):5116-23. doi: 10.1158/1078-0432.CCR-07-4506.

PMID:
18698029
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.

Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio-Donahue C, Hidalgo M.

Mol Cancer Ther. 2007 Mar;6(3):1079-88.

PMID:
17363501
[PubMed - indexed for MEDLINE]
Free Article
17.

Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.

Li B, Chang CM, Yuan M, McKenna WG, Shu HK.

Cancer Res. 2003 Nov 1;63(21):7443-50.

PMID:
14612544
[PubMed - indexed for MEDLINE]
Free Article
18.

Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.

Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.

World J Gastroenterol. 2012 Nov 21;18(43):6226-34. doi: 10.3748/wjg.v18.i43.6226.

PMID:
23180942
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS.

J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103. doi: 10.1093/jnci/djn216. Epub 2008 Jul 29.

PMID:
18664652
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.

Gysin S, Lee SH, Dean NM, McMahon M.

Cancer Res. 2005 Jun 1;65(11):4870-80.

PMID:
15930308
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk